Americans for Safe Access Medical Information:
In response to claims that cannabis has “no accepted medical value”, Americans for Safe Access has collected research on cannabinoids and the therapeutic use of cannabis.
Medical Cannabis Research:
Definitions and important concepts about medical cannabis (marijuana)
A database of clinical research and case reports, from the last 30 years, maintained by the International Association for Cannabis.
Health and Human Services claims that “marijuana has no currently accepted medical use in treatment in the United States.” However, more than 6,500 reports and journal articles from around the world support the medical value of cannabis (marijuana). Here is an overview of the latest research.
August 16th, 2005
A thorough history of medical marijuana prepared by medical marijuana expert, Dr. Lester Grinspoon.
In 1997 the National Institutes of Health held a 2-day scientific meeting about medical marijuana. According to the panel, research is justified into symptoms of certain conditions including pain, neurological and movement disorders, nausea, loss of appetite and severe weight loss, and glaucoma.
In 1999, the Institute of Medicine released their report, on the potential health benefits and risks of marijuana. They stress the need for more scientific research.
Based on the effects of cannabinoids in pre-clinical models of neuropathic pain and anecdotal case reports, a controlled trial of smoked cannabis was conducted.
In this study designed to examine the long term effects of smoked cannabis, researchers reviewed the overall health of patients who have used medical marijuana legally under federal law for 11-27 years. Results demonstrate clinical effectiveness in treating glaucoma, chronic musculoskeletal pain, spasm and nausea, and spasticity of multiple sclerosis.
by Ken Mackie, Annual Review of Pharmacology and Toxicology
March 14th, 2006
by Uberto Pagotto, Giovanni Marsicano, Daniela Cota, Beat Lutz, and Renato Pasquali, Endocrine Reviews
February 1st, 2006
The United Kingdom’s Advisory Council on the Misuse of Drugs recommends the reclassification of all Cannabis preparations from Class B to Class C.
In light of new research, the United Kingdom’s Advisory Council reviewed its position on the classification of cannabis products in light of new research. This new report confirms the Council’s 2002 decision.